Neogenomics (NEO) Fundamental Analysis: Revenue, Earnings & Valuation

0.48 / 10

Underperform

Fundamental analysis rates the stock as Underperform, with a 0.5/10 quality score. Asset‑MV and cash increase are modest positives, while profit‑MV, revenue‑MV and net‑income ratios are negative, indicating challenging earnings and limited upside.

Analysis Checks(6/10)

Revenue-MV

Value-0.06

Score1/3

Weight57.56%

1M Return-2.72%

Net cash flow from operating activities / Operating revenue (%)

Value0.72

Score2/3

Weight-20.72%

1M Return0.90%

Profit-MV

Value0.66

Score1/3

Weight65.25%

1M Return-2.85%

Net income-Revenue

Value-0.04

Score1/3

Weight58.41%

1M Return-2.58%

Net profit margin (%)

Value-14.85

Score2/3

Weight-15.81%

1M Return0.68%

Cash-UP

Value-2.29

Score3/3

Weight-68.57%

1M Return2.45%

Net cash flow from operating activities / Total liabilities (%)

Value0.01

Score1/3

Weight85.78%

1M Return-4.08%

EBIT / Total operating revenue (%)

Value-15.89

Score2/3

Weight-22.72%

1M Return1.01%

Asset-MV

Value-0.55

Score2/3

Weight-23.37%

1M Return0.95%

Net profit / Total operating revenue (%)

Value-14.85

Score2/3

Weight-15.81%

1M Return0.68%

Is NEO undervalued or overvalued?

NEO scores 0.48/10 on fundamentals and holds a Premium valuation at present. Backed by its -12.42% ROE, -14.85% net margin, -8.92 P/E ratio, 1.15 P/B ratio, and -35.48% earnings growth, these metrics solidify its Underperform investment rating.